Alternatives to Human Blood and Blood Resources
Biotechnology is increasingly providing alternatives to established transfusion products, with the promise of freedom from infectivity and unlimited supply. Such products must demonstrate a safety and efficacy at least as great as current products, and thereafter an improved cost‐benefit ratio. Alte...
Gespeichert in:
| Veröffentlicht in: | Vox sanguinis 1998-06, Vol.74 (S2), p.21-28 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | S2 |
| container_start_page | 21 |
| container_title | Vox sanguinis |
| container_volume | 74 |
| creator | Prowse, C.V. |
| description | Biotechnology is increasingly providing alternatives to established transfusion products, with the promise of freedom from infectivity and unlimited supply. Such products must demonstrate a safety and efficacy at least as great as current products, and thereafter an improved cost‐benefit ratio. Alternatives to established products may be categorised as:
•
Alternatives made from blood donations.
•
Substitutes (acting by distinct mechanisms).
•
Recombinant analogs.
•
Cellular therapies (including gene therapy).
This overview covers the current status in each of these categories, and likely trends in the near future. Recombinant therapeutic proteins are already established in certain indications, and are likely to be extended to a wider range of applications as the methods for bulk production are improved. Alternative products from donated blood should find niche indications, especially for acute therapy, but cellular therapy is unlikely to be widely implemented on this timescale, except as an adjunct in life‐threatening indications. Substitutes are perhaps the most interesting category and are expected to have a major impact, particularly through the use of “poietins” to stimulate endogenous production of circulating cell populations. |
| doi_str_mv | 10.1111/j.1423-0410.1998.tb05396.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73876809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73876809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4646-bba7290903da804e424ac5b8130f6a17f12f12683b5eefa162182c400a0d76a3</originalsourceid><addsrcrecordid>eNqVkE-L1EAQxRtR1nH1IwjDIt4yW_2_40XWUWeExcV1UW9FJelAxkyydic6--3tMGEO3mwauuj61avHY-yCw4qnc7lbcSVkBmr6yHO3GgrQMjerwyO2OLUeswWAElkOYJ-yZzHuAMAJp8_YWW5BJW7BLq_awYeOhua3j8uhX27HPXXLd23fV0vqqrm69bEfQ-njc_akpjb6F_N7zu4-frhbb7Prm82n9dV1ViqjTFYUZEUOOciKHCivhKJSF45LqA1xW3ORrnGy0N7XxI3gTpQKgKCyhuQ5e32UvQ_9r9HHAfdNLH3bUuf7MaKVzhoHeQIv_gF3yWiXrKEQUoPm3CbozREqQx9j8DXeh2ZP4QE54JQo7nCKDafYcEoU50TxkIZfzhvGYu-r0-gcYeq_mvsUS2rrQF3ZxBMmpDOgXcLeHrE_Tesf_sMAfrv5MVVJITsqNHHwh5MChZ9orLQav3_e4PrL19v3ZrNFLf8CUrafHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223505117</pqid></control><display><type>article</type><title>Alternatives to Human Blood and Blood Resources</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Karger Journals Complete</source><creator>Prowse, C.V.</creator><creatorcontrib>Prowse, C.V.</creatorcontrib><description>Biotechnology is increasingly providing alternatives to established transfusion products, with the promise of freedom from infectivity and unlimited supply. Such products must demonstrate a safety and efficacy at least as great as current products, and thereafter an improved cost‐benefit ratio. Alternatives to established products may be categorised as:
•
Alternatives made from blood donations.
•
Substitutes (acting by distinct mechanisms).
•
Recombinant analogs.
•
Cellular therapies (including gene therapy).
This overview covers the current status in each of these categories, and likely trends in the near future. Recombinant therapeutic proteins are already established in certain indications, and are likely to be extended to a wider range of applications as the methods for bulk production are improved. Alternative products from donated blood should find niche indications, especially for acute therapy, but cellular therapy is unlikely to be widely implemented on this timescale, except as an adjunct in life‐threatening indications. Substitutes are perhaps the most interesting category and are expected to have a major impact, particularly through the use of “poietins” to stimulate endogenous production of circulating cell populations.</description><identifier>ISSN: 0042-9007</identifier><identifier>EISSN: 1423-0410</identifier><identifier>DOI: 10.1111/j.1423-0410.1998.tb05396.x</identifier><identifier>PMID: 9704423</identifier><identifier>CODEN: VOSAAD</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Animals, Genetically Modified ; Biological and medical sciences ; Biological Products ; Biotechnology ; Blood ; Blood Proteins - genetics ; Blood Proteins - therapeutic use ; Blood Substitutes ; Blood Transfusion ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Hematopoietic Cell Growth Factors - pharmacology ; Hematopoietic Stem Cell Mobilization ; Humans ; Medical sciences ; Protein Engineering ; Recombinant Proteins - therapeutic use ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Vox sanguinis, 1998-06, Vol.74 (S2), p.21-28</ispartof><rights>1998 S. Karger AG, Basel</rights><rights>1998 INIST-CNRS</rights><rights>Copyright S. Karger AG Jun 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4646-bba7290903da804e424ac5b8130f6a17f12f12683b5eefa162182c400a0d76a3</citedby><cites>FETCH-LOGICAL-c4646-bba7290903da804e424ac5b8130f6a17f12f12683b5eefa162182c400a0d76a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1423-0410.1998.tb05396.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1423-0410.1998.tb05396.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,1417,23930,23931,25140,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2386058$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9704423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prowse, C.V.</creatorcontrib><title>Alternatives to Human Blood and Blood Resources</title><title>Vox sanguinis</title><addtitle>Vox Sang</addtitle><description>Biotechnology is increasingly providing alternatives to established transfusion products, with the promise of freedom from infectivity and unlimited supply. Such products must demonstrate a safety and efficacy at least as great as current products, and thereafter an improved cost‐benefit ratio. Alternatives to established products may be categorised as:
•
Alternatives made from blood donations.
•
Substitutes (acting by distinct mechanisms).
•
Recombinant analogs.
•
Cellular therapies (including gene therapy).
This overview covers the current status in each of these categories, and likely trends in the near future. Recombinant therapeutic proteins are already established in certain indications, and are likely to be extended to a wider range of applications as the methods for bulk production are improved. Alternative products from donated blood should find niche indications, especially for acute therapy, but cellular therapy is unlikely to be widely implemented on this timescale, except as an adjunct in life‐threatening indications. Substitutes are perhaps the most interesting category and are expected to have a major impact, particularly through the use of “poietins” to stimulate endogenous production of circulating cell populations.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Animals, Genetically Modified</subject><subject>Biological and medical sciences</subject><subject>Biological Products</subject><subject>Biotechnology</subject><subject>Blood</subject><subject>Blood Proteins - genetics</subject><subject>Blood Proteins - therapeutic use</subject><subject>Blood Substitutes</subject><subject>Blood Transfusion</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Hematopoietic Cell Growth Factors - pharmacology</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Protein Engineering</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0042-9007</issn><issn>1423-0410</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE-L1EAQxRtR1nH1IwjDIt4yW_2_40XWUWeExcV1UW9FJelAxkyydic6--3tMGEO3mwauuj61avHY-yCw4qnc7lbcSVkBmr6yHO3GgrQMjerwyO2OLUeswWAElkOYJ-yZzHuAMAJp8_YWW5BJW7BLq_awYeOhua3j8uhX27HPXXLd23fV0vqqrm69bEfQ-njc_akpjb6F_N7zu4-frhbb7Prm82n9dV1ViqjTFYUZEUOOciKHCivhKJSF45LqA1xW3ORrnGy0N7XxI3gTpQKgKCyhuQ5e32UvQ_9r9HHAfdNLH3bUuf7MaKVzhoHeQIv_gF3yWiXrKEQUoPm3CbozREqQx9j8DXeh2ZP4QE54JQo7nCKDafYcEoU50TxkIZfzhvGYu-r0-gcYeq_mvsUS2rrQF3ZxBMmpDOgXcLeHrE_Tesf_sMAfrv5MVVJITsqNHHwh5MChZ9orLQav3_e4PrL19v3ZrNFLf8CUrafHg</recordid><startdate>199806</startdate><enddate>199806</enddate><creator>Prowse, C.V.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>S. Karger AG</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>199806</creationdate><title>Alternatives to Human Blood and Blood Resources</title><author>Prowse, C.V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4646-bba7290903da804e424ac5b8130f6a17f12f12683b5eefa162182c400a0d76a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Animals, Genetically Modified</topic><topic>Biological and medical sciences</topic><topic>Biological Products</topic><topic>Biotechnology</topic><topic>Blood</topic><topic>Blood Proteins - genetics</topic><topic>Blood Proteins - therapeutic use</topic><topic>Blood Substitutes</topic><topic>Blood Transfusion</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Hematopoietic Cell Growth Factors - pharmacology</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Protein Engineering</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prowse, C.V.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Vox sanguinis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prowse, C.V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alternatives to Human Blood and Blood Resources</atitle><jtitle>Vox sanguinis</jtitle><addtitle>Vox Sang</addtitle><date>1998-06</date><risdate>1998</risdate><volume>74</volume><issue>S2</issue><spage>21</spage><epage>28</epage><pages>21-28</pages><issn>0042-9007</issn><eissn>1423-0410</eissn><coden>VOSAAD</coden><abstract>Biotechnology is increasingly providing alternatives to established transfusion products, with the promise of freedom from infectivity and unlimited supply. Such products must demonstrate a safety and efficacy at least as great as current products, and thereafter an improved cost‐benefit ratio. Alternatives to established products may be categorised as:
•
Alternatives made from blood donations.
•
Substitutes (acting by distinct mechanisms).
•
Recombinant analogs.
•
Cellular therapies (including gene therapy).
This overview covers the current status in each of these categories, and likely trends in the near future. Recombinant therapeutic proteins are already established in certain indications, and are likely to be extended to a wider range of applications as the methods for bulk production are improved. Alternative products from donated blood should find niche indications, especially for acute therapy, but cellular therapy is unlikely to be widely implemented on this timescale, except as an adjunct in life‐threatening indications. Substitutes are perhaps the most interesting category and are expected to have a major impact, particularly through the use of “poietins” to stimulate endogenous production of circulating cell populations.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9704423</pmid><doi>10.1111/j.1423-0410.1998.tb05396.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0042-9007 |
| ispartof | Vox sanguinis, 1998-06, Vol.74 (S2), p.21-28 |
| issn | 0042-9007 1423-0410 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73876809 |
| source | MEDLINE; Access via Wiley Online Library; Karger Journals Complete |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Animals, Genetically Modified Biological and medical sciences Biological Products Biotechnology Blood Blood Proteins - genetics Blood Proteins - therapeutic use Blood Substitutes Blood Transfusion Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Hematopoietic Cell Growth Factors - pharmacology Hematopoietic Stem Cell Mobilization Humans Medical sciences Protein Engineering Recombinant Proteins - therapeutic use Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Alternatives to Human Blood and Blood Resources |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T21%3A36%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alternatives%20to%20Human%20Blood%20and%20Blood%20Resources&rft.jtitle=Vox%20sanguinis&rft.au=Prowse,%20C.V.&rft.date=1998-06&rft.volume=74&rft.issue=S2&rft.spage=21&rft.epage=28&rft.pages=21-28&rft.issn=0042-9007&rft.eissn=1423-0410&rft.coden=VOSAAD&rft_id=info:doi/10.1111/j.1423-0410.1998.tb05396.x&rft_dat=%3Cproquest_cross%3E73876809%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223505117&rft_id=info:pmid/9704423&rfr_iscdi=true |